G12D
· 5 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12D | “One of the predominant mutant KRAS G12D variants is responsible for pancreatic cancer and is an attractive drug target.” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “A novel avenue for the control of KRAS G12C and G12D mutations is made possible by flavonoids.” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “Among all the mutations in exon 12 and exon 13 of the KRAS gene, the G12D mutation is more prevalent in pancreatic and lung cancer and accounts for around 41% of all G12 mutations, making them potential anticancer therapeutic targets.” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “In KRAS, mutations of G12D and G12C are common.” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “The physicochemical analysis predicted mutation in wild-type KRAS protein had adapted negative charge on single base substitution of G12D that may easily cause loss of interactions and result in critical differences in the structure and function of the protein.” | 0.82 | literature_variant_regex_v2 |